Business Context and Reporting Period
This Form 8-K is filed by Aerpio Pharmaceuticals, Inc. (not Whitehawk Therapeutics, Inc., as indicated in the metadata) on August 11, 2021. The filing serves to announce the company's financial results for the quarter ended June 30, 2021. The company is an emerging growth company listed on the Nasdaq Capital Market under the symbol ARPO.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the press release furnished as Exhibit 99.1, which is not included in the input text.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only confirms the announcement of Q2 2021 results.
Guidance, Outlook, and Risks
The text does not contain management commentary, guidance, outlook, or specific risk factors. It includes a standard disclaimer stating that the information furnished under Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the discrepancy between the metadata company name ("Whitehawk Therapeutics, Inc.") and the actual registrant ("Aerpio Pharmaceuticals, Inc.").
- Review Exhibit 99.1 (the press release) to obtain specific Q2 2021 financial figures, as they are absent from this 8-K cover sheet.
- Confirm the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Check the Nasdaq Capital Market listing status for ticker ARPO.